Genetic alterations of m6A regulators predict poorer survival in acute myeloid leukemia - PubMed (original) (raw)
Genetic alterations of m6A regulators predict poorer survival in acute myeloid leukemia
Chau-To Kwok et al. J Hematol Oncol. 2017.
Erratum in
- Erratum to: Genetic alterations of m6A regulators predict poorer survival in acute myeloid leukemia.
Kwok CT, Marshall AD, Rasko JE, Wong JJ. Kwok CT, et al. J Hematol Oncol. 2017 Feb 17;10(1):49. doi: 10.1186/s13045-017-0419-x. J Hematol Oncol. 2017. PMID: 28212678 Free PMC article. No abstract available.
Abstract
Methylation of N6 adenosine (m6A) is known to be important for diverse biological processes including gene expression control, translation of protein, and messenger RNA (mRNA) splicing. However, its role in the development of human cancers is poorly understood. By analyzing datasets from the Cancer Genome Atlas Research Network (TCGA) acute myeloid leukemia (AML) study, we discover that mutations and/or copy number variations of m6A regulatory genes are strongly associated with the presence of TP53 mutations in AML patients. Further, our analyses reveal that alterations in m6A regulatory genes confer a worse survival in AML. Our work indicates that genetic alterations of m6A regulatory genes may cooperate with TP53 and/or its regulator/downstream targets in the pathogenesis and/or maintenance of AML.
Keywords: Acute myeloid leukemia; Leukemia; RNA modification; TP53 mutation; m6A.
Figures
Fig. 1
Kaplan-Meier curves for overall and event-free survival of TCGA AML patients by the presence and absence of a mutation of m6A regulatory genes, b mutation and/or copy number variation (CNV) of m6A regulatory genes, and c deletion/copy number loss of the ALKBH5 gene encoding an important m6A “eraser.” Mutations include point mutation, deep deletion, and amplification. Log-rank test was used to determine significance. +, censored data. d Multivariate analysis for overall and event-free survival in TCGA AML patients
References
- Li Z, Weng H, Su R, Weng X, Zuo Z, Li C, Huang H, Nachtergaele S, Dong L, Hu C, Qin X, Tang L, Wang Y, Hong G-M, Huang H, Wang X, Chen P, Gurbuxani S, Arnovitz S, Li Y, Li S, Strong J, Neilly MB, Larson RA, Jiang X, Zhang P, Jin J, He C, Chen J. FTO plays an oncogenic role in acute myeloid leukemia as a N6-methyladenosine RNA demethylase. Cancer Cell. 2017;31:127–141. doi: 10.1016/j.ccell.2016.11.017. - DOI - PMC - PubMed
- Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C, Schultz N. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401–404. doi: 10.1158/2159-8290.CD-12-0095. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous